PT - JOURNAL ARTICLE AU - Koyama, Satoshi AU - Wang, Ying AU - Paruchuri, Kaavya AU - Uddin, Md Mesbah AU - Cho, So Mi J. AU - Urbut, Sarah M. AU - Haidermota, Sara AU - Hornsby, Whitney E. AU - Green, Robert C. AU - Daly, Mark J. AU - Neale, Benjamin M. AU - Ellinor, Patrick T. AU - Smoller, Jordan W. AU - Lebo, Matthew S. AU - Karlson, Elizabeth W. AU - Martin, Alicia R. AU - Natarajan, Pradeep TI - Decoding Genetics, Ancestry, and Geospatial Context for Precision Health AID - 10.1101/2023.10.24.23297096 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.24.23297096 4099 - http://medrxiv.org/content/early/2023/10/25/2023.10.24.23297096.short 4100 - http://medrxiv.org/content/early/2023/10/25/2023.10.24.23297096.full AB - Mass General Brigham, an integrated healthcare system based in the Greater Boston area of Massachusetts, annually serves 1.5 million patients. We established the Mass General Brigham Biobank (MGBB), encompassing 142,238 participants, to unravel the intricate relationships among genomic profiles, environmental context, and disease manifestations within clinical practice. In this study, we highlight the impact of ancestral diversity in the MGBB by employing population genetics, geospatial assessment, and association analyses of rare and common genetic variants. The population structures captured by the genetics mirror the sequential immigration to the Greater Boston area throughout American history, highlighting communities tied to shared genetic and environmental factors. Our investigation underscores the potency of unbiased, large-scale analyses in a healthcare-affiliated biobank, elucidating the dynamic interplay across genetics, immigration, structural geospatial factors, and health outcomes in one of the earliest American sites of European colonization.Competing Interest StatementDeclaration of interests K.P. reports research grants, paid to her institution, from Allelica, Apple, Amgen, AstraZeneca, Boston Scientific, Genentech / Roche, and Ionis. R.C.G. has received compensation for advising the following companies: Allelica, Atria, Fabric, Genome Web, Genomic Life and Juniper Genomics; and is co-founder of Genome Medical and Nurture Genomics. M.J.D is a founder of Maze Therapeutics and is a member of the scientific advisory board for Neumora Therapeutics, Inc. (formerly known as RBNC Therapeutics). B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora Therapeutics, Inc. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has received grant support from Biogen, Inc. P.T.E. receives sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for MyoKardia and Bayer AG. J.W.S. is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. P.N. reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple, AstraZeneca, Blackstone Life Sciences, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV, HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme, Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work.Funding StatementS.K. is supported by Japan Society for the Promotion of Science (202160643), Uehara Memorial Foundation, and National Institute of Health (NIH), National Heart Lung and Blood Institute (NHLBI, K99HL169733). K.P is supported by the MGH Executive Committee for Research Fund for Medical Discovery. S.J.C. is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI19C1330). S.M.U. is supported by NIH National Human Genetics Research Institute (NHGRI, T32HG010464). R.C.G. is supported by NIH (HG009922, OD026553, HL143295, TR003201). B.M.N. is supported by R37MH107649. P.T.E. is supported by grants from the NIH (1R01HL092577, 1R01HL157635, 5R01HL139731), from the American Heart Association (18SFRN34230127, 961045), and from the European Union (MAESTRIA 965286). J.W.S. is supported by OT2OD026553, U01HG008685, MH118233. M.L. is supported by grants from the NIH (OT2OD002750, R01HL143295, U01HG008685, U01TR003201, and U24HG006834). E.K. is supported by grants from the NIH (OT2OD026553, U01HG008685, P30 AR070253, OT2HL161841). A.R.M. and Y.W. are supported by NIH, NHGRI (K99/R00MH117229 to A.R.M.) and by European Unions Horizon 2020 research and innovation program under grant agreement 101016775. A.R.M. is also supported by U01HG011719. P.N. is supported by grants from the NHLBI (R01HL127564), and NHGRI (U01HG011719).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol to analyze Mass General Brigham Biobank data was approved by the Mass General Brigham Institutional Review Board under protocol number 2018P001236. The study protocols to analyze UKBB data was approved under protocol number 2021P002228 and performed under UKBB application number 7089.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenotyping and exome sequencing data for 13,500 participants from the MGBB are available in dbGAP (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002018.v1.p1). Additional MGBB data were accessed under institutional review board protocol for this current study and are not publicly available due to restrictions on the data. The summary statistics for phenome-wide common/rare variant association analysis and the allele frequencies of genetic clusters will be publically available upon the publication. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002018.v1.p1